

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Marshall Richard Henry</u> <hr/> (Last) (First) (Middle) <u>6272 W. 91ST AVENUE</u> <hr/> (Street) <u>WESTMINSTER CO 80031</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/29/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>TriSalus Life Sciences, Inc. [ TLSI ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <u>Chief Medical Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>30,000<sup>(1)(2)</sup></u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Employee Stock Option (right to buy)</u>	<u>(3)</u>	<u>11/14/2034</u>	<u>Common Stock</u>	<u>25,000<sup>(1)</sup></u>	<u>4.01</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(4)</u>	<u>07/07/2035</u>	<u>Common Stock</u>	<u>48,000<sup>(1)</sup></u>	<u>4.96</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(5)</u>	<u>11/24/2035</u>	<u>Common Stock</u>	<u>60,000<sup>(1)</sup></u>	<u>5.55</u>	<u>D</u>	

**Explanation of Responses:**

- The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective June 29, 2026.
- Consists of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in four equal annual installments commencing on the one-year anniversary of the grant date of November 24, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
- One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of November 14, 2024 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.
- One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of June 2, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.
- One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

**Remarks:**

/s/ Mary Szela, Attorney-in-Fact 06/29/2026

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB**

Number.